it was patented in 1982 and approved for medical use in 1992 it is marketed by novartis in europe australia new zealand japan south korea and the philippines as navoban but is not available in the u s it is also available from novell pharmaceutical laboratories and marketed in several asian countries as setrovel tropisetron acts as both a selective 5 ht receptor antagonist and nicotinic receptor agonist tropisetron is a well tolerated drug with few side effects headache constipation and dizziness are the most commonly reported side effects associated with its use hypotension transient liver enzyme elevation immune hypersensitivity syndromes and extrapyramidal side effects have also been associated with its use on at least one occasion there have been no significant drug interactions reported with this drug s use it is broken down by the hepatic cytochrome p450 system and it has little effect on the metabolism of other drugs broken down by this system as a biological stain and as trypanocide